Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InspireMD (NSPR) Gains from Sales and Divestitures (2016 - 2024)

Historic Gains from Sales and Divestitures for InspireMD (NSPR) over the last 10 years, with Q4 2024 value amounting to $1.1 million.

  • InspireMD's Gains from Sales and Divestitures rose 47338.91% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.1 million, marking a year-over-year increase of 47338.91%. This contributed to the annual value of $1.1 million for FY2024, which is 47338.91% up from last year.
  • Per InspireMD's latest filing, its Gains from Sales and Divestitures stood at $1.1 million for Q4 2024, which was up 47338.91% from $186510.0 recorded in Q4 2023.
  • In the past 5 years, InspireMD's Gains from Sales and Divestitures registered a high of $1.1 million during Q4 2024, and its lowest value of $11000.0 during Q4 2020.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $186510.0 (2023), whereas its average is $306110.8.
  • Per our database at Business Quant, InspireMD's Gains from Sales and Divestitures soared by 21990000.0% in 2020 and then tumbled by 962.74% in 2023.
  • InspireMD's Gains from Sales and Divestitures (Quarter) stood at $11000.0 in 2020, then surged by 420.34% to $57237.0 in 2021, then skyrocketed by 260.57% to $206379.0 in 2022, then dropped by 9.63% to $186510.0 in 2023, then surged by 473.39% to $1.1 million in 2024.
  • Its Gains from Sales and Divestitures was $1.1 million in Q4 2024, compared to $186510.0 in Q4 2023 and $206379.0 in Q4 2022.